<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00068744</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-22011-40014</org_study_id>
    <secondary_id>EORTC-22011</secondary_id>
    <secondary_id>EORTC-40014</secondary_id>
    <nct_id>NCT00068744</nct_id>
  </id_info>
  <brief_title>Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer</brief_title>
  <official_title>Continuous Fluorouracil Plus Mitomycin C Versus Mitomycin C Plus Cisplatin As Chemotherapy Combination In Combined Radiochemotherapy For Locally Advanced Anal Cancer. A Phase II-III Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as mitomycin, fluorouracil, and cisplatin, use&#xD;
      different ways to stop tumor cells from dividing so they stop growing or die. Combining&#xD;
      radiation therapy with chemotherapy may kill more tumor cells. It is not yet known whether&#xD;
      radiation therapy and mitomycin are more effective when combined with fluorouracil or with&#xD;
      cisplatin in treating anal cancer .&#xD;
&#xD;
      PURPOSE: This randomized phase II/III trial is studying how well giving radiation therapy and&#xD;
      mitomycin together with fluorouracil works compared to radiation therapy, mitomycin, and&#xD;
      cisplatin in treating patients with locally advanced anal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Phase II&#xD;
&#xD;
        -  Primary&#xD;
&#xD;
             -  Compare the early clinical response (tumor response at 8 weeks) of patients with&#xD;
                locally advanced anal cancer treated with radiotherapy with mitomycin and cisplatin&#xD;
                vs mitomycin and fluorouracil.&#xD;
&#xD;
        -  Secondary&#xD;
&#xD;
             -  Compare the feasibility of these regimens in these patients.&#xD;
&#xD;
             -  Compare the acute toxicity of these regimens in these patients.&#xD;
&#xD;
             -  Compare patient compliance to these regimens.&#xD;
&#xD;
      Phase III&#xD;
&#xD;
        -  Primary&#xD;
&#xD;
             -  Compare the event-free survival of patients treated with these regimens.&#xD;
&#xD;
        -  Secondary&#xD;
&#xD;
             -  Compare colostomy-free, disease-free, and overall survival of patients treated with&#xD;
                these regimens.&#xD;
&#xD;
             -  Compare locoregional control in patients treated with these regimens.&#xD;
&#xD;
             -  Compare the late toxicity of these regimens in these patients.&#xD;
&#xD;
             -  Compare quality of life of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      participating center, T stage (T2 vs T3 vs T4), and nodal status (N0 vs N+). Patients are&#xD;
      randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients undergo radiotherapy once daily 5 days a week on weeks 1-4, 7-8, and 3&#xD;
           days of week 9 (total of 33 fractions). Patients concurrently receive fluorouracil IV&#xD;
           continuously on days 1-26 and 43-59 and mitomycin IV over 15 minutes on days 1 and 43.&#xD;
&#xD;
        -  Arm II: Patients receive radiotherapy and mitomycin as in arm I and cisplatin IV over 1&#xD;
           hour on days 1, 8, 15, 22, 43, 50, and 57.&#xD;
&#xD;
      In both arms, treatment continues in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline, at weeks 12 and 26, and then every 6 months for 2&#xD;
      years.&#xD;
&#xD;
      Patients are followed every 2 weeks for 8 weeks, at week 26, and then every 6 months&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 678 patients (80 [40 per treatment arm] for phase II and 598&#xD;
      [299 per treatment arm] for phase III) will be accrued for this study within 2-5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual&#xD;
  </why_stopped>
  <start_date>July 2003</start_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Response as measured by RECIST at 8 weeks after completion of study treatment (Phase II)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-free survival as measured by Logrank at 12 and 26 weeks, then every 6 months thereafter (Phase III)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity and compliance to treatment as measured by CTC v 2.0 at completion of study treatment (Phase II)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colostomy-free survival as measured by Logrank at 12 and 26 weeks, then every 6 months thereafter (Phase III)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival as measured by Logrank at 12 and 26 weeks, then every 6 months thereafter</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival as measured by Logrank at 12 and 26 weeks, then every 6 months thereafter</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local control as measured by Gray at 12 and 26 weeks, then every 6 months thereafter</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicity as measured by RTOG and EROTC every 6 months after week 26</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by EORTC Quality of Life Questionnaire-C30 and ASCT at 12 and 26 weeks, then every 6 months for 2 years after entry</measure>
  </secondary_outcome>
  <enrollment type="Actual">88</enrollment>
  <condition>Anal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitomycin C</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed squamous cell anal carcinoma&#xD;
&#xD;
               -  Keratinizing or non-keratinizing&#xD;
&#xD;
               -  The following stages are eligible:&#xD;
&#xD;
                    -  T2, N0, M0 with maximum tumor diameter at least 4 cm&#xD;
&#xD;
                    -  T3-T4, N0, M0&#xD;
&#xD;
                    -  Any T, N1-N3, M0&#xD;
&#xD;
          -  Tumor located in the anal canal OR in the anal margin and infiltrating the anal canal&#xD;
&#xD;
          -  No primary adenocarcinoma of the anus&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 75&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Granulocyte count greater than 2,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine less than 1.4 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No grade I angina pectoris with clinical symptoms within the past 3 months&#xD;
&#xD;
          -  No grade II-IV angina pectoris within the past 3 months&#xD;
&#xD;
          -  No stage II or greater distal arteritis&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other prior malignancy except adequately treated basal cell skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude study compliance and follow-up&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No other concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  No prior colostomy&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior treatment for anal cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Francois Bosset, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hopital Jean Minjoz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ziekenhuis Netwerk Antwerpen Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <zip>B-2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cazk Groeninghe - Campus Maria's Voorzienigheid</name>
      <address>
        <city>Kortrijk</city>
        <zip>B-8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Sint-Augustinus</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute of Egypt</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84082</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Klinik - Universitaetsklinikum Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>D-52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite - Campus Charite Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>D-10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Roessle Comprehensive Cancer Center - Charite Campus Buch</name>
      <address>
        <city>Berlin</city>
        <zip>D-13122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>D-45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Halle</name>
      <address>
        <city>Halle</city>
        <zip>D-06097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis - Leer</name>
      <address>
        <city>Leer</city>
        <zip>D-26789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Sant Anna</name>
      <address>
        <city>Como</city>
        <zip>22100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Busonera - Divisione Oncologia Medica</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arnhems Radiotherapeutisch Instituut</name>
      <address>
        <city>Arnhem</city>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Bernard Verbeeten Instituut</name>
      <address>
        <city>Tilburg</city>
        <zip>5042 SB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology and Radiology of Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Egypt</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Serbia</country>
  </location_countries>
  <removed_countries>
    <country>Former Serbia and Montenegro</country>
  </removed_countries>
  <results_reference>
    <citation>Matzinger O, Roelofsen F, Mineur L, Koswig S, Van Der Steen-Banasik EM, Van Houtte P, Haustermans K, Radosevic-Jelic L, Mueller RP, Maingon P, Collette L, Bosset JF; EORTC Radiation Oncology and Gastrointestinal Tract Cancer Groups. Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014). Eur J Cancer. 2009 Nov;45(16):2782-91. doi: 10.1016/j.ejca.2009.06.020. Epub 2009 Jul 28.</citation>
    <PMID>19643599</PMID>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>September 10, 2003</study_first_submitted>
  <study_first_submitted_qc>September 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2003</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>squamous cell carcinoma of the anus</keyword>
  <keyword>stage II anal cancer</keyword>
  <keyword>stage IIIA anal cancer</keyword>
  <keyword>stage IIIB anal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anus Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

